Announced Date: 2025-08-05 (August 5, 2025) Licensor: XtalPi Inc. (China) Licensee: DoveTree Medicines（US） . Scope of … [Technology Collaboration] XtalPi and Dovetree enters a 6 billion USD Collaboration on AI drug discoveryRead more
Author: admin
[China BD Deal] CSPC and Madrigal achieved a 2 billion license on GLP-1 R SYH2086
Announced Date: 2025-07-30 (JULY 30, 2025) Asset Name: SYH2086 Licensor: CSPC Pharmaceutical Group Limited (HKEX Stock … [China BD Deal] CSPC and Madrigal achieved a 2 billion license on GLP-1 R SYH2086Read more
[China BD 2025] Hengrui and GSK achieved a 12.5 billion USD license on PDE3/4 inhibitor HRS-9821 and 11 other assets
Announced Date: 2025-07-28 (JULY 28, 2025) Asset Name: HRS-9821 and other 11 preclinical medicines Licensor: Hengrui … [China BD 2025] Hengrui and GSK achieved a 12.5 billion USD license on PDE3/4 inhibitor HRS-9821 and 11 other assetsRead more
[China BD Deal] 3SBio and Pfizer Completes a 6 billion License on PD-1/VEGF BsAbs SSGJ-707
Announced Date: 2025-05-19 (May 19, 2025), 2025-07-24 updated Asset Name: SSGJ-707 Licensor: 3SBio, Inc (01530.HK) (Headquarter Shanghai … [China BD Deal] 3SBio and Pfizer Completes a 6 billion License on PD-1/VEGF BsAbs SSGJ-707Read more
[China BD 2025] Mabwell Bioscience and Calico Life Sciences Enters a 596 million USD License for IL-11 Targeting Monoclonal Antibody 9MW3811
Announced Date: 2025-06-26 (June 26, 2025) Asset Name: 9MW3811 Licensor: Mabwell (Shanghai) Bioscience (China) Licensee (Buyer): … [China BD 2025] Mabwell Bioscience and Calico Life Sciences Enters a 596 million USD License for IL-11 Targeting Monoclonal Antibody 9MW3811Read more
[China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020
Announced Date: 2025-06-22 (June 22, 2025) Asset Name: HBM7020 Licensor (Seller): Harbour BioMed (China) Licensee (Buyer): … [China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020Read more
[Technology Collaboration] CSPC and AstraZeneca enters a 5.3 billion USD Collaboration on AI-enabled drug research
Announced Date: 2025-06-13 (June 13, 2025) Licensor: CSPC (CSPC Pharmaceuticals Group Limited. , China) Licensee: AstraZeneca（UK） Collaboration … [Technology Collaboration] CSPC and AstraZeneca enters a 5.3 billion USD Collaboration on AI-enabled drug researchRead more
[China BD 2025] Intragrand and Transpire enters a license on PDE4 inhibitor ITG-1052
Announced Date: 2025-06-03 (June 3, 2025) Asset Name: ITG-1052 (Lenamilast) Licensor: Suzhou Intragrand Pharma (China) Licensee … [China BD 2025] Intragrand and Transpire enters a license on PDE4 inhibitor ITG-1052Read more
[China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus)
Announced Date: 2025-06-02 (June 2, 2025) Asset Name: BNT327 (PM8002 from Biotheus) Licensor: Biopharmaceutical New Technologies … [China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus)Read more
[China BD deal 2025]Hansoh and Regeneron enters a 2 billion USD license on GLP-1/GIP Ra HS-20094
Announced Date: 2025-06-02 (June 2, 2024) Asset Name: HS-20094 Licensor: Hansoh (Hansoh Pharmaceuticals Group, China) Licensee … [China BD deal 2025]Hansoh and Regeneron enters a 2 billion USD license on GLP-1/GIP Ra HS-20094Read more